Recombinant XIII type collagen as well as preparation method and application thereof
By designing and optimizing the amino acid and nucleotide sequences of human type XIII collagen, recombinant proteins with high cellular and hemocompatibility were prepared, which solved the problem of poor wound healing and antibacterial effects in the prior art, and achieved the Efficient wound healing and antibacterial and anti-inflammatory effects.
Patent Information
- Application Number
- CN202411141002.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
Smart Images

Figure CN119019536A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a recombinant type XIII collagen and a preparation method and application thereof. Background Art
[0002] Biomaterials are substitutes for human biological tissues that have the ability to interact with the human body. They can be natural or synthetic. Collagen is the most abundant protein in mammals and it constitutes the main component of the extracellular matrix. Collagen is mainly involved in the formation of the fibrous and microfibrillar network of the extracellular matrix, basement membrane and other extracellular matrix structures.
[0003] Recombinant collagen is a biomaterial obtained by using genetic engineering editing technology to recombinantly express a specific type of human collagen gene coding sequence (at least the full-length or partial sequence of the helical domain), a partial sequence of different types of collagen gene coding, or an artificially designed gene coding as a template through a modification process such as assembly, editing, and optimization. Because it can achieve similar biocompatibility and physicochemical properties to collagen extracted from animal tissues, recombinant collagen has strong hydrophilicity and liquid absorption, can absorb tissue exudates, and lay a scaffold for the migration and proliferation of epidermal cells.
[0004] Wound healing is a tightly organized biological repair process involving a series of overlapping and interdependent cascade reactions such as hemostasis, inflammatory response, cell proliferation and migration, collagen deposition, and re-epithelialization. Based on the functional characteristics of genetically optimized and modified recombinant collagen, the second-class recombinant collagen wound dressing medical device products in the form of liquid, paste, gel, fiber, sponge, etc. are prepared and widely used in biological tissue engineering fields such as wound care, liquid absorption and hemostasis, and gynecological mucosal repair. In particular, recombinant collagen wound dressings can be used for superficial small traumas and abrasions in the superficial dermis and above caused by accidental injuries, surgery, ulcers, etc., providing a good nutritional basis for wound healing, with more outstanding biodegradability, and more potential for clinical application than traditional dressings.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a recombinant type XIII collagen and a preparation method and application thereof. The recombinant type XIII collagen obtained by the preparation method of the present invention has good cell compatibility and blood compatibility, antibacterial and angiogenesis-enhancing abilities, and can effectively promote wound healing.
[0007] The present invention is achieved in that:
[0008] The present invention uses the sequence of human type XIII collagen as a reference and selects three peptide segments in the helical region of human type XIII collagen, namely the amino acid sequences shown in SEQ ID NO.1-3:
[0009] SEQ ID NO.1:
[0010] GPPGPTGRPGLPGDKGAIGMPGRVGSPGDAGLSIIGPRGPPGQPGTR GFPGFPGPIGLDGKPGHPGPKGDMGLTGPPGQPGPQGQKGEKGQCGEY;
[0011] SEQ ID NO.2:
[0012] GPPGPPGPPGPSGPLGHPGLPGPMGPPGLPGPPGPKGDPGIQGYHGRKGERGMPGMPGKHGAKGAPGIAVAGMKGEPGIPGTKGEKGAEGSPGLPGLLGQKGEKGDAGNSIGGGGEPGPPGLPGPPGPKGEAGVDGQVGPPGQPGDKGERGAAGEQGPDGPKGSKGEPGKG;
[0013] SEQ ID NO.3:
[0014] GPPGLPGQIGPPGAPGIPGQKGEIGLPGPPGHDGEKGPRGKPGDMGPPGPQGPPGKDGPPGVKGENGHPGSPGEKGEKGETGQAGSPGEKGEAGEKGNPGAEVPGLPGPEGPPGPPGL QGVPPGPKGEAGLDGAKGEKGFQGEKGDRGPLGLPGASGLDGRPGPPGTPGPIGVPGPAGPKGERGSKGDPGMTGPTGAAGLPGLHGPPGDKGNRGERGKKGSRGPKGDKGDQGAPGLD.
[0015] The amino acids are connected in sequence to obtain a new type XIII collagen, the amino acid sequence of which is shown in SEQ ID NO.4:
[0016] GPGPTGRPGLPGDKGAIGMPGRVGSPGDAGLSIIGPRGPPGQPGTRGFPGFPGPIGLDGKPGHPGPKGDMGLTGPPGQPGPQGQKGEKGQCGEY GPPGPPGPPGPSGPLGHPGLPGPMGPPGLPGPPGPKGDPGIQGYHGRKGERGMPGMPGKHGAKGAPGIAVAGMKGEPGIPGTKGEKGAEGSPGLPGLLGQKG EKGDAGNSIGGGRGEPGPPGLPGPPGPKGEAGVDGQVGPPGQPGDKGERGAAGEQGPDGPKGSKGEPGKGGPPGLPGQIGPPGAPGIPGQKGEIGLPGPPGH DGEKGPRGKPGDMGPPGPQGPPGKDGPPGVKGENGHPGSPGEKGEKGETGQAGSPGEKGEAGEKGNPGAEVPGLPGPEGPPGPPGLQGVPPGKGEAGLDGAK GEKGFQGEKGDRGPLGLPGASGLDGRPGPPGTPGPIGVPGPAGPKGERGSKGDPGMTGPTGAAGLPGLHGPPGDKGNRGERGKKGSRGPKGDKGDQGAPGLD.
[0017] Based on this, the technical solution of the present invention is as follows:
[0018] In a first aspect, the present invention provides a recombinant type XIII collagen, the amino acid sequence of which is any one of the following (A1)-(A3):
[0019] (A1) the amino acid sequence shown in SEQ ID NO.4;
[0020] (A2) an amino acid sequence having the same functional protein obtained by replacing, deleting or inserting one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.4;
[0021] (A3) The amino acid sequence of a fusion protein obtained by connecting a protein tag to the N-terminus or / and C-terminus of (A1) or (A2).
[0022] Connecting protein tags at both ends of the above amino acid sequence can facilitate subsequent protein separation and purification, or detection, tracing, etc. Common protein tags include His, GST, MBP, CBD, Strep-tag, Halo-Tag, SNAP-tag, SUMO, NusA, TrxA, DsbA, Flag and c-Myc.
[0023] In a second aspect, the present invention provides the above-mentioned recombinant type XIII collagen-related biomaterial, which is any one of the following (B1)-(B4):
[0024] (B1) a nucleic acid molecule encoding the above-mentioned recombinant type XIII collagen;
[0025] (B2) an expression cassette containing the nucleic acid molecule of (B1);
[0026] (B3) a recombinant vector containing the nucleic acid molecule of (B1), or a recombinant vector containing the expression cassette of (B2);
[0027] (B4) A recombinant microorganism containing the nucleic acid molecule of (B1), a recombinant microorganism containing the expression cassette of (B2), or a recombinant microorganism containing the recombinant vector of (B3).
[0028] Based on codon preference, the present invention optimizes the nucleotide sequence of the above-mentioned recombinant type XIII collagen. The optimized nucleotide sequence is shown in SEQ ID NO.5:
[0029]
[0030] However, the nucleotide sequence that can be obtained for the recombinant type XIII collagen according to the present invention is not limited to the sequence shown in SEQ ID NO.5, but can also be a DNA molecule that has 80% or more identity with the nucleotide sequence shown in SEQ ID NO.5 and encodes the recombinant type XIII collagen.
[0031] In a second aspect, the present invention also provides a method for preparing the above-mentioned recombinant type XIII collagen, which comprises: inserting a nucleotide sequence into an expression vector to obtain a recombinant vector, then introducing the recombinant vector into a host cell, culturing the recombinant cell, collecting and separating and purifying the cell culture to obtain the recombinant type XIII collagen.
[0032] In some embodiments, the host cells include prokaryotic cells and eukaryotic cells. Prokaryotic cells include Escherichia coli, Bacillus subtilis and Bacillus licheniformis; eukaryotic cells include Pichia pastoris, Saccharomyces cerevisiae, animal cells and plant cells; preferably, the host cell is Pichia pastoris.
[0033] In the present invention, the expression vector is a self-replicating DNA molecule conventional in the art that can transfer DNA fragments (target genes) to host cells. It can be changed according to different host cells, and the present invention is not limited to this.
[0034] As for the separation and purification method, it includes one or a combination of methods such as salting out, ultrafiltration, affinity chromatography and gel filtration chromatography, and membrane separation is preferred.
[0035] In a third aspect, the present invention also provides the use of recombinant type XIII collagen or the above-mentioned biomaterial in the preparation of a product promoting wound healing.
[0036] In a fourth aspect, the present invention also provides the use of recombinant type XIII collagen or the above-mentioned biomaterial in the preparation of antibacterial and anti-inflammatory products.
[0037] Experiments have shown that the recombinant type XIII collagen prepared by the present invention has high cell compatibility and blood compatibility, and also has the ability to inhibit harmful bacteria such as Escherichia coli, Staphylococcus aureus and methicillin-resistant Staphylococcus aureus, and can promote cell proliferation, accelerate blood coagulation and promote wound healing. Therefore, the recombinant type XIII collagen of the present invention can be used to prepare tissue engineering materials or medical devices such as subcutaneous fillers, artificial bones, artificial skins, oral absorbable biofilms, bone implants, vascular stents, intercellular matrix stents and collagen sponges.
[0038] In a fifth aspect, the present invention also provides a product for promoting wound healing, which contains the above-mentioned recombinant type XIII collagen as an active ingredient.
[0039] In a sixth aspect, the present invention further provides an antibacterial and anti-inflammatory product, which contains the above-mentioned recombinant type XIII collagen as an active ingredient.
[0040] The present invention has the following beneficial effects:
[0041] (1) The type XIII collagen of the present invention is much shorter than natural human collagen, so the protein translated from it has a small molecular weight and is easy to prepare.
[0042] (2) The type XIII collagen of the present invention has the ability to inhibit harmful bacteria, accelerate blood coagulation and promote wound healing.
[0043] (3) The preparation method of type XIII collagen of the present invention is simple and easy to operate, and is suitable for industrial large-scale production, and thus has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0045] Figure 1 is the plasmid map of pPICZαA-XIII-α1 constructed in Example 1;
[0046] Figure 2 This is the electrophoresis detection result of the XIII recombinant collagen in Example 1. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0048] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0049] Example 1
[0050] This example is the preparation of recombinant collagen type XIII in a yeast expression system, and the specific steps are as follows:
[0051] 1. Preparation of shuttle plasmid and yeast expression strain
[0052] (1) The amino acid sequence of the recombinant type XIII collagen shown in SEQ ID NO.4 was optimized for the codons of the yeast expression system to obtain an optimized type XIII target gene sequence (SEQ ID NO.5). The obtained target gene sequence was commissioned to Qingke Biotechnology Co., Ltd. for gene synthesis. The synthesized gene was ligated into the pPICZαA plasmid to obtain the pPICZαA-XIII-α1 plasmid. Figure 1 shown.
[0053] (2) pPICZαA-XIII-α1 was linearized with Pme XIII and then transformed into Pichia pastoris X-33 competent cells. Bleomycin resistance was used as a selection marker to screen transformants to obtain a yeast expression strain.
[0054] 2. Induced expression of target protein
[0055] (1) Pick a single colony of the constructed yeast expression strain and add it to 5 ml of YPD liquid medium (1% yeast extract, 2% peptone and 2% glucose), and culture it at 30°C and 200 rpm for 48 h for activation;
[0056] (2) Transfer the inoculum to a 500 ml Erlenmeyer flask (containing 200 ml of YPD culture medium) at a 1% inoculum volume and culture at 30°C and 200 rpm for 24 h to serve as the seed for the tank.
[0057] (3) Prepare 3 L of BSM medium and add it to a 5 L fermenter, sterilize at 121° C. for 20 min, and after cooling to 30° C., adjust the pH to 5.0, and add the seeds prepared in (2) to the fermenter by flame inoculation for fermentation;
[0058] (4) Cultivate until OD 600 When OD was 70, 50% glycerol was added until 600 When the temperature reaches about 120, stop adding, and wait until the dissolved oxygen rebounds to 100%, then start adding methanol for induction;
[0059] (5) During the induction process, the dissolved oxygen was controlled to be not less than 30% and the pH was about 5.0. The induction was carried out for 40 hours, and the fermentation was terminated. The culture medium was centrifuged at 12000 rpm for 2 minutes, and the supernatant was taken for detection of protein yield and purity by grayscale scanning and SDS-PAGE.
[0060] The yield of XIII recombinant collagen prepared by the above method was detected by SDS-PAGE method. The results showed that the result showed a single band without obvious mixed bands. The protein electrophoresis results were as follows: Figure 2 shown.
[0061] 3. Collagen purification
[0062] The collected supernatant is passed through an ultrafiltration membrane, and then through a hollow fiber column and freeze-dried to obtain recombinant collagen type XIII.
[0063] (1) Add NaCl with a final concentration of 10% to the crude protein supernatant collected by centrifugation, stir to dissolve, let stand at room temperature for 2 hours, centrifuge at 9000 rpm for 10 minutes, and collect the supernatant. The collected supernatant is concentrated and desalted by a 30KD ultrafiltration membrane.
[0064] (2) The pH of the concentrated and desalted protein supernatant was adjusted to 6.5 with phosphoric acid, loaded onto a cation exchange resin, and the target protein was obtained after elution with 0.5 M NaCl;
[0065] (3) The collected target protein solution was desalted by a 30KD ultrafiltration membrane, and then pre-frozen in a -20°C refrigerator for 4 hours, and then transferred to a vacuum freeze dryer for freeze drying. After 48 hours, the freeze-dried protein was collected, which was collagen XIII.
[0066] Example 2
[0067] This example is a test of the antibacterial activity of the type XIII recombinant collagen obtained in Example 1, as follows:
[0068] Gram-negative Escherichia coli, Gram-positive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus were used as target strains. The concentration of the three bacterial suspensions was diluted to 10 7 CFU / mL. 1×10 7 CFU / mL of three target bacteria were cultured for 24 hours. The blank group was a bacterial suspension, the control group was a commercially available natural XIII collagen (purchased from Feiyue Biological) with a concentration of 60 mg / L, and the experimental group was a recombinant XIII collagen of different concentrations. The prepared recombinant collagen samples of different concentrations were added to the well plate, and three parallels were set for each concentration. They were placed in a 37°C incubator and cultured for 12 hours, 24 hours, and 48 hours. At the end of the culture, 100 μL of the test strain suspension was respectively aspirated onto the LB solid culture medium, and a sterile coating rod was used to quickly and evenly spread it. The plates were cultured at 37°C for 24 hours, and the number of viable bacteria was recorded.
[0069] Relative antibacterial activity (%) = number of bacterial colonies in the experimental group / number of bacterial colonies in the control group
[0070] Table 1 Relative antibacterial activity of recombinant collagen protein XIII at different concentrations
[0071]
[0072] According to the results in Table 1, different concentrations of XIII recombinant collagen have inhibitory effects on the target strains. When the concentration of recombinant collagen is 60 mg / L, the inhibition rate of the three target strains reaches the highest. Compared with the commercially available natural XIII collagen, the antibacterial effect is more significant.
[0073] Example 3
[0074] This example is a verification test of the effect of type XIII recombinant collagen obtained in Example 1 on the density of regenerated blood vessels, as follows:
[0075] Thirty-six rats with full-thickness infected skin defect models were randomly divided into six groups. One group was a blank group, in which infected rats were not treated; one group was a control group, which was treated with commercially available natural XIII collagen (purchased from Feiyue Biotechnology); and the remaining four groups were experimental groups, which were treated with different concentrations of XIII recombinant collagen. After the treatment, the wound was first wrapped with gauze, and then medical tape was wrapped around the gauze to better fix the dressing. Wound tissue samples were collected on the 10th day, and CD31 (an endothelial cell marker) was used to detect vascular endothelial cells to assess the level of angiogenesis at the wound site.
[0076] Table 2 Density of blood vessel regeneration on day 7 after different concentrations of recombinant collagen XIII
[0077]
[0078] The results of the regenerated blood vessel density on the 10th day are shown in Table 2. As the concentration of XIII recombinant collagen sample increases, the number of blood vessel regeneration also increases. When the concentration reaches 5.0 mg / mL, the regenerated blood vessel density is the highest. At the same time, compared with the commercially available natural XIII collagen, XIII recombinant collagen has a significant effect on promoting blood vessel density.
[0079] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A recombinant type XIII collagen, characterized in that: The amino acid sequence of the recombinant type XIII collagen is any one of the following (A1)-(A3): (A1) the amino acid sequence shown in SEQ ID NO.4; (A2) an amino acid sequence having the same functional protein obtained by replacing, deleting or inserting one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.4; (A3) The amino acid sequence of a fusion protein obtained by connecting a protein tag to the N-terminus or / and C-terminus of (A1) or (A2).
2. The biomaterial related to the recombinant type XIII collagen according to claim 1, characterized in that: Any one of the following (B1)-(B4): (B1) a nucleic acid molecule encoding the recombinant type XIII collagen according to claim 1; (B2) an expression cassette containing the nucleic acid molecule described in (B1); (B3) a recombinant vector containing the nucleic acid molecule described in (B1), or a recombinant vector containing the expression cassette described in (B2); (B4) A recombinant microorganism containing the nucleic acid molecule described in (B1), or a recombinant microorganism containing the expression cassette described in (B2), or a recombinant microorganism containing the recombinant vector described in (B3).
3. The biomaterial according to claim 2, characterized in that The nucleotide sequence of the nucleic acid molecule is any one of the following (C1)-(C2): (C1) a DNA molecule as shown in SEQ ID NO.5; (C2) A DNA molecule having 80% or more identity with the nucleotide sequence defined in (C1) and encoding the recombinant type XIII collagen.
4. The method for preparing recombinant type XIII collagen according to claim 1, characterized in that: include: The nucleotide sequence is inserted into an expression vector to obtain a recombinant vector, and then the recombinant vector is introduced into a host cell. The recombinant cell is cultured, and the cell culture is collected, separated and purified to obtain the recombinant type XIII collagen.
5. The preparation method according to claim 4, characterized in that: The host cells include prokaryotic cells and eukaryotic cells; Preferably, the prokaryotic cells include: Escherichia coli, Bacillus subtilis and Bacillus licheniformis; the eukaryotic cells include Pichia pastoris, Saccharomyces cerevisiae, animal cells and plant cells; Preferably, the host cell is Pichia pastoris.
6. Use of the recombinant type XIII collagen according to claim 1 or the biomaterial according to claim 2 or 3 in the preparation of a product for promoting wound healing.
7. Use of the recombinant type XIII collagen according to claim 1 or the biomaterial according to claim 2 or 3 in the preparation of antibacterial and anti-inflammatory products.
8. The use according to claim 6 or 7, characterized in that: The products include subcutaneous fillers, artificial bones, artificial skin, oral absorbable biomembranes, bone implants, vascular scaffolds, intercellular matrix scaffolds and collagen sponges.
9. A product for promoting wound healing, characterized in that: The product contains the recombinant type XIII collagen described in claim 1 as an active ingredient.
10. An antibacterial and anti-inflammatory product, characterized in that: The product contains the recombinant type XIII collagen described in claim 1 as an active ingredient.
